MedTrace Logo

Treatment of Graves' Hyperthyroidism With Selenium Plus Methimazole

NCT02727738 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2016-04-06

No results posted yet for this study

Summary

Evaluation of the efficacy of the combined treatment (methimazole plus selenium) in the control of hyperthyroidism as compared to methimazole alone in 30 Graves' disease (GD) untreated patients.

Conditions

  • Graves' Disease

Interventions

DIETARY_SUPPLEMENT

Selenium

Selenium 80 mg bid for 90 days

DRUG

Methimazole

Methimazole starting dose depending on FT3 values (15 mg/day or 20 mg/day or 30 mg/day, for FT3 values \<10 pg/ml, 10-15 pg/ml, \>15 pg/ml, respectively) to be tapered by 5 mg/day every 15 days down to values sufficient for FT3 to be normal

Sponsors & Collaborators

  • University of Pisa

    lead OTHER

Principal Investigators

  • Claudio Marcocci, MD · Department of Clinical and Experimental Medicine, University of Pisa

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-01-31
Primary Completion
2015-09-30
Completion
2015-12-31

Countries

  • Italy

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02727738 on ClinicalTrials.gov